Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Conjupro Biotherapeutics, Inc.
Atavistik Bio, Inc
Alterome Therapeutics, Inc.
Eli Lilly and Company
BeOne Medicines
ViroMissile, Inc.
Tizona Therapeutics, Inc
Clasp Therapeutics, Inc.
Eli Lilly and Company
IDEAYA Biosciences
Eli Lilly and Company
Doma Biopharmaceutical(Suzhou)Co., Ltd.
Innate Pharma
MOMA Therapeutics
NeoTX Therapeutics Ltd.
Exelixis
Senhwa Biosciences, Inc.
Jonsson Comprehensive Cancer Center
Novita Pharmaceuticals, Inc.
NextPoint Therapeutics, Inc.
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Theratechnologies
Oxford Vacmedix UK Ltd.
Agenus Inc.
Carisma Therapeutics Inc
Eli Lilly and Company
NGM Biopharmaceuticals, Inc
Danatlas Pharmaceuticals Co., Ltd
Pfizer
NGM Biopharmaceuticals, Inc
Haihe Biopharma Co., Ltd.
Pfizer
Leap Therapeutics, Inc.
M.D. Anderson Cancer Center
Hoffmann-La Roche
Canadian Cancer Trials Group
Xencor, Inc.
Impact Therapeutics, Inc.
Quadriga Biosciences, Inc.
Xencor, Inc.
Ludwig Institute for Cancer Research
Imperial College London
MacroGenics
MacroGenics
AstraZeneca
Impact Therapeutics, Inc.
National Institutes of Health Clinical Center (CC)
Abramson Cancer Center at Penn Medicine